The major dithiothreitol-resistant phospholipase A2 activity present in the cytosol of U937 cells has been purified >200,000-fold by sequential chromatography on phenyl-SPW, heparin-Sepharose CL-6B, high-performance hydroxylapatite, TSK-gel G3000-SW, and Mono Q columns. This 110-kDa cytosolic phospholipase A2 is distinct from the relatively small (14-kDa) dithiothreitol-sensitive phospholipases A2 that are secreted from many cell types. This additional phospholipase A2 selectively hydrolyzes fatty acid at the sn-2 position of the glycerol and favors phospholipids containing arachidonic acid, which is the rate-limiting precursor for prostaglandin and leukotriene production. Interestingly, a >5-fold increase in phospholipase A2 activity is noted as the calcium concentration increases from the levels found in resting cells to those observed in activated macrophages. We suggest that this enzyme and not the previously described secretory phospholipase A2 is activated by cytosolic effectors such as GTP-binding regulatory proteins and protein kinases to initiate the production of prostaglandins, leukotrienes, and plateletactivating factor. To distinguish this cytosolic enzyme from the previously described secretory ones, we suggest referring to it as cPLA2 for cytosolic phospholipase A2 and collectively referring to the secretory phospholipases A2 as sPLA2s.Arachidonic acid is released from the sn-2 position of the glycerol in membrane phospholipids by an activated form of phospholipase A2 (PLA2) to initiate the synthesis of two potent classes ofinflammatory mediators, prostaglandins and leukotrienes (1-3). The other product of the PLA2 reaction is a lysophospholipid, which can serve as a precursor to the inflammatory mediator platelet-activating factor (PAF) (4). It is widely held that the production of arachidonic acid and lysophospholipid represents the rate-limiting step in the production of prostaglandins, leukotrienes, and plateletactivating factor. Therefore, agents that stimulate the production of these inflammatory mediators are likely to do so by modulating the activity of PLA2. However, the mechanism by which PLA2 activity is regulated remains poorly understood. To date, most of the direct studies on PLA2 have been structural or mechanistic and have focused on the extracellular enzymes isolated from snake venom or mammalian pancreas (5-9). Recently, the secretory granules of platelets and neutrophils have been shown to contain phospholipases A2 (PLA2s) that are structurally similar to the venom and pancreatic enzymes (10-12). There is accumulating evidence, however, that eicosanoid production is regulated by a PLA2 located in the cytosol.A number of different studies have shown that when cells are treated with phorbol 12-myristate 13-acetate (PMA), a potent activator of the cytosolic enzyme protein kinase C, an increase in prostaglandin, leukotriene, and platelet-activating factor production is observed (13-16). Interestingly, when the PLA2 activity present in the cytosolic fraction of PMAtreated cel...